Bildkälla: Stockfoto

Cantargia: Planning for the next steps - Nordea

The past few months have been very positive for Cantargia. Most encouraging, in our view, is the recently published and promising interim results for its ongoing phase IIa CANFOUR trial. In its Q3 report, Cantargia repeated the message that it is planning its next steps forward. We argue that these next steps –along with the full results from CANFOUR and the readouts from Novartis's canakinumab trials – represent the next key triggers for the share.

https://research.nordea.com/api/reportfileapi?id=635519&channel=Finwire

Marketing material commissioned by Cantargia.
Börsvärldens nyhetsbrev
ANNONSER